Demonstrates the efficacy of high-affinity single-domain antibodies for broad-spectrum SARS-CoV-2 detection, suggesting significant diagnostic potential.
The rapid evolution of SARS-CoV-2 presents substantial challenges to maintaining diagnostic accuracy. Single-domain antibodies (variable domains of camelid heavy-chain antibodies, VHHs), commonly referred to as nanobodies, are attractive tools for diagnostic applications due to their high specificity, stability, affinity and expression yield. In this study, three high-affinity VHHs that recognize the receptor-binding domain (RBD) of the SARS-CoV-2 BA.2 variant were isolated from a large naïve alpaca VHH phage display library. These nanobodies exhibited nanomolar affinities and high thermal stability. Notably, reformatting one VHH into a bivalent VHH-Fc fusion construct, K115.2-Fc, enhanced binding affinity 24-fold, achieving an equilibrium dissociation constant of 68.3 picomolar. Functional characterization demonstrated that K115.2-Fc cross-reacted with the Wuhan SARS-CoV-2 RBD and multiple variants, including Alpha, Beta, Gamma, Delta, Kappa, BA.1, BA.2, and BA.4/5. In indirect enzyme-linked immunosorbent assay, K115.2-Fc detected full-length spike protein with a limit of detection of 8.1 pM. Moreover, it enabled sensitive detection in western blotting and flow cytometry, highlighting its applicability across diverse diagnostic applications. Collectively, these findings identify K115.2-Fc as a promising candidate with potential for SARS-CoV-2 diagnostic utility.
No takes yet. Share an insight, caveat, or question.
Cho et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: